Tranexamic acid is a well-established ingredient in dermatology, originally used as a hemostatic agent but now widely adopted in cosmetic skincare for its ability to inhibit the interaction between keratinocytes and melanocytes, reducing UV-triggered melanin synthesis. When combined with a broad-spectrum SPF 50 base, it creates a compelling dual-action product: the UV filters block the UV radiation that triggers hyperpigmentation, while the tranexamic acid addresses the biochemical cascade that leads to dark spot formation even in the presence of imperfect UV protection.
For cosmetic use, the effective concentration range is 2% to 5%. The majority of published clinical data on topical tranexamic acid for melasma and post-inflammatory hyperpigmentation uses a 2% to 3% concentration applied twice daily over 8–12 weeks. At 5%, some studies show faster visible improvement but with a diminishing returns curve above 3%. For an SPF product used in the morning only, 3% is a common and defensible formulation target.
Stability is the primary formulation challenge. Tranexamic acid is water-soluble, pH-sensitive, and must be incorporated into the water phase of an emulsion. It is relatively stable at pH 5.5–7.0, which aligns well with most sunscreen emulsion systems. However, it can interact with anionic polymers (like carbomer) and some chelating agents, so your cosmetic chemist must screen for compatibility carefully. At higher temperatures (above 45°C), some degradation can occur, making accelerated stability testing especially important for this active.
From a safety standpoint, tranexamic acid has a strong tolerability profile in topical applications. It is non-irritating at cosmetic concentrations for the vast majority of skin types, including sensitive skin, which makes it a strong pairing with SPF for daily use without concerns about phototoxicity — a limitation of some other brightening actives like retinoids or AHAs. The EU limits tranexamic acid in cosmetics to 2% under Annex III of EC 1223/2009, which is the primary regulatory consideration for EU-market formulations.
For a US market product, tranexamic acid is not an FDA-recognized sunscreen active and plays no role in the OTC drug portion of the product label. It sits in the inactive or cosmetic ingredient portion of a sunscreen OTC drug product and is listed in the inactive ingredients section of the Drug Facts panel. This is a nuance many first-time SPF founders miss, and it matters for how you word claims. You can market the brightening benefit in your product description and marketing copy, but the Drug Facts panel is governed by the OTC monograph and does not accommodate cosmetic actives claims.
When evaluating manufacturers for this formula type, ask specifically whether their cosmetic chemist has formulated tranexamic acid into an SPF base before and request the stability data. This single question will quickly separate experienced suppliers from those who are agreeing to try something new on your budget.
Ingredients in this answer: Tranexamic Acid · Carbomer
Read the full guide on Private Label Tranexamic Acid SPF 50 Sunscreen Manufacturer Low MOQ →